EGFR and KRAS mutations in patients with adenocarcinoma of the lung. - Wikidata - wikimedia - TriplyDB

EGFR and KRAS mutations in patients with adenocarcinoma of the lung.

EGFR and KRAS mutations in patients with adenocarcinoma of the lung.

http://www.wikidata.org/entity/Q37205334

about

Epidemiology of Lung Cancer in Korea: Recent Trends Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors.Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung.Epidermal growth factor receptor mutations in colorectal cancer patients Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma.Gefitinib in Selected Patients with Pre-Treated Non-Small-Cell Lung Cancer: Results from a Phase IV, Multicenter, Non-Randomized Study (SELINE)Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors.CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment.Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study.Epidermal growth factor receptor mutation in adenocarcinoma lung in a North Indian population: Prevalence and relation with different clinical variables.EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features.CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer.Establishment and characterization of primary lung cancer cell lines from Chinese population.PAR-4 as a possible new target for pancreatic cancer therapy.The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer.Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy.Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients.Diethylnitrosamine induces lung adenocarcinoma in FVB/N mouse.

P2860

Q28077423-9FCE6BFF-C4E3-40A2-A94C-AA6CC3E9130C Q33847505-E2B9BEBD-9484-4FB7-9845-0D005184564B Q34637855-51D5F3DB-7A57-46EB-8035-2544C3D47DD7 Q34952066-AAABEFC5-5ABA-4A6D-B58A-C629D3C1462A Q35134625-12318355-9CEC-4D5E-88E5-92D89E4D3EEF Q35897344-D9DA08C0-4373-479D-887D-2FFEE8FD2C8D Q36512046-9B0956B9-621C-463E-9E04-56B07FDF833A Q36690945-3D7A3424-2D12-48CA-B80C-591CAC8F44C7 Q37051421-2DAA4568-F35E-4674-AFE6-7E4086D72E35 Q37102688-F14D4CDB-F1EA-4631-993A-358EEE85C8E6 Q37265114-3AFD1FFC-7081-4948-BDE0-D27E01F90424 Q37421036-F72D961D-B6CE-4798-90CE-56406DA65BB4 Q37633163-6850895D-43CE-4A38-9A51-AF6973AB4DD7 Q37728841-73921E16-3B5F-4008-8456-039C18A3781E Q37738894-C8F01188-D558-4876-AC96-2AA202508E92 Q38306683-E1BD768A-E69A-4CD9-9EB6-086B6D11723B Q38859701-193377CD-2F39-4AAE-B647-C89C66C4FEAC Q39205689-C49FB8CF-D42C-4A5C-A0DB-D306A3EC2C35 Q44669701-DC2F5935-1578-4FBF-AEFE-04FD434AE4C0 Q49166137-BED23BB2-8F22-4FE5-AADF-CB52AB92041F

P2860

EGFR and KRAS mutations in patients with adenocarcinoma of the lung.

http://www.wikidata.org/entity/Q37205334

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

EGFR and KRAS mutations in patients with adenocarcinoma of the lung.

@en

EGFR and KRAS mutations in patients with adenocarcinoma of the lung.

@nl

type

label

EGFR and KRAS mutations in patients with adenocarcinoma of the lung.

@en

EGFR and KRAS mutations in patients with adenocarcinoma of the lung.

@nl

prefLabel

EGFR and KRAS mutations in patients with adenocarcinoma of the lung.

@en

EGFR and KRAS mutations in patients with adenocarcinoma of the lung.

@nl

P1433

Q37205334-2F7CCA2D-AEF0-42C4-883E-140A67641C5A

P1476

Q37205334-94C48C2E-623A-4012-8FF8-DB843C57B25D

P2093

Q37205334-06F7C40F-472B-40C0-8533-C2CD10833CBD

Q37205334-1F081253-7A5E-4ECB-9014-0B3A8B5A32B4

Q37205334-27CF5392-F14C-4188-BABE-672A6614611E

Q37205334-B1D6AD66-31B2-49A3-9216-F77BE47CF340

Q37205334-D9F72340-47F9-403C-B863-87F3839B16BB

P2860

Q37205334-0ADC0213-0D71-409E-A70B-C50471333092

Q37205334-0E4BB22E-6136-4B88-B601-DCCBB7910ABA

Q37205334-11A0E4D6-A256-4130-9186-0E97F5FA82A6

Q37205334-1A8AA0B9-634B-4384-A244-668F038AF92A

Q37205334-1D63073C-860A-48D1-9372-78D872DBA002

Q37205334-2AFE4FC4-18C0-4B31-807C-775924300703

Q37205334-30BF78B5-5BCB-4FDC-AAEB-A6B87C6DD340

Q37205334-37888974-3F5D-4A66-B937-DA86EF97B92E

Q37205334-3A03B19E-5E90-4EBD-A824-398478551FD9

Q37205334-4379173D-7B1F-4C3C-BF08-71E87086413E

P304

Q37205334-228F3B66-4174-4DEA-B4FD-2397A63C5B71

P31

Q37205334-0177CD1C-70FB-4ADE-9A3A-F17302DCD862

P356

Q37205334-3F8A4A4D-7E03-44D0-8789-1483C6AE7804

P433

Q37205334-A60C2606-F5DF-4F07-940C-764B0DF68659

P478

Q37205334-14FB5FC8-92EE-4250-9ABD-B94239144C5F

P577

Q37205334-9C791DBE-9D4E-44D6-8CD5-F6336D1FB6F7

P698

Q37205334-1E29CD22-DD57-41D3-95FE-2097F46DDEFF

P921

Q37205334-D7BEAA18-7E06-4A80-9480-C54FF1691BFB

P932

Q37205334-8E43AFD5-6655-41D7-B6AF-D6CB2A47E25E

P356

KJIM.2009.24.1.43

P1433

The Korean journal of internal medicine

P1476

EGFR and KRAS mutations in patients with adenocarcinoma of the lung.

@en

P2093

Chul Ho Oak

http://www.w3.org/2001/XMLSchema#string

Hee Kyung Chang

http://www.w3.org/2001/XMLSchema#string

Mann Hong Jung

http://www.w3.org/2001/XMLSchema#string

Soon Jung Suo

http://www.w3.org/2001/XMLSchema#string

Tae Won Jang

http://www.w3.org/2001/XMLSchema#string

P2860

The protein kinase complement of the human genome

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women.

Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung.

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

Targeting the epidermal growth factor receptor for cancer therapy.

Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia.

P304

48-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3904/KJIM.2009.24.1.43

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19270482

http://www.w3.org/2001/XMLSchema#string

P921

P932

2687655

http://www.w3.org/2001/XMLSchema#string